Dolutegravir
An integrase strand transfer inhibitor used as part of combination antiretroviral therapy for HIV infection, working by blocking the viral integrase enzyme that incorporates HIV's genetic material into human cell DNA. It is highly effective, has a high barrier to resistance, and is recommended as a preferred component of first-line HIV treatment. It is also available in combination pills to reduce the number of tablets patients need to take daily.
Moleküler Ağırlık
419,4000 g/mol
LogP
2,40
TPSA
99,20 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
2D Yapı
Cite this structure
Embed this structure
SMILES
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
InChI
InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
Molecular Formula
C20H19F2N3O5
HBD / HBA
2 / 8
Döndürülebilir Bağlar
3
Ağır Atomlar
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An integrase strand transfer inhibitor used as part of combination antiretroviral therapy for HIV infection, working by blocking the viral integrase enzyme that incorporates HIV's genetic material into human cell DNA. It is highly effective, has a high barrier to resistance, and is recommended as a preferred component of first-line HIV treatment. It is also available in combination pills to reduce the number of tablets patients need to take daily.
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Yes, Dolutegravir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1229211. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54726191. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dolutegravir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dolutegravir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dolutegravir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dolutegravir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dolutegravir"></drugfyi-drug>